Bausch + Lomb Co. (NYSE:BLCO) Receives $20.58 Average Price Target from Analysts

Shares of Bausch + Lomb Co. (NYSE:BLCO) have been given a consensus rating of “Hold” by the thirteen brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $20.58.

Several brokerages have weighed in on BLCO. Morgan Stanley downgraded Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a report on Monday, December 2nd. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Bausch + Lomb in a research note on Thursday, December 12th. Royal Bank of Canada upped their target price on Bausch + Lomb from $20.00 to $23.00 and gave the company an “outperform” rating in a research report on Tuesday, October 22nd. Evercore ISI upgraded shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $19.00 to $25.00 in a report on Tuesday, October 15th. Finally, Stifel Nicolaus lifted their price objective on shares of Bausch + Lomb from $16.00 to $19.00 and gave the company a “hold” rating in a research note on Monday, September 23rd.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. King Street Capital Management L.P. acquired a new stake in shares of Bausch + Lomb during the 3rd quarter valued at about $14,122,000. Clearline Capital LP boosted its position in Bausch + Lomb by 136.8% during the second quarter. Clearline Capital LP now owns 712,055 shares of the company’s stock worth $10,339,000 after purchasing an additional 411,404 shares in the last quarter. Whitebox Advisors LLC grew its holdings in Bausch + Lomb by 28.2% in the second quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company’s stock valued at $22,447,000 after purchasing an additional 339,643 shares during the period. Barclays PLC purchased a new stake in shares of Bausch + Lomb in the third quarter valued at approximately $5,797,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Bausch + Lomb during the 3rd quarter worth approximately $4,331,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Stock Down 1.3 %

Bausch + Lomb stock opened at $17.85 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. The firm has a market cap of $6.29 billion, a P/E ratio of -17.00, a P/E/G ratio of 1.74 and a beta of 0.47. Bausch + Lomb has a twelve month low of $13.16 and a twelve month high of $21.69. The business has a fifty day moving average of $19.03 and a two-hundred day moving average of $17.93.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the company earned $0.22 earnings per share. The business’s revenue for the quarter was up 18.8% on a year-over-year basis. On average, analysts forecast that Bausch + Lomb will post 0.6 earnings per share for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.